Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients.

ABSTRACT:

Background

Glioblastoma is the commonest malignant brain tumor and has a very poor prognosis. Reduced expression of the MGMT gene (10q26.3), influenced primarily by the methylation of two differentially methylated regions (DMR1 and DMR2), is associated with a good response to temozolomide treatment. However, suitable methods for detecting the methylation of the MGMT gene promoter and setting appropriate cutoff values are debated.

Results

A cohort of 108 patients with histologically and genetically defined glioblastoma was retrospectively examined with methylation-specific Sanger sequencing (sSeq) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) methods. The DMR2 region was methylated in 29% of samples, whereas DMR1 was methylated in 12% of

SUBMITTER: Lhotska H 

PROVIDER: S-EPMC11776323 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature